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Summary. Experimental studies have suggested that angio- 
tensin-converting enzyme (ACE) inhibitors may have an im- 
portant role in blocking the progression of and/or reversing 
endothelial dysfunction. The extrapolation of these experi- 
mental studies to the clinical situation has, however, been 
disappointing. Studies of forearm-mediated endothelial vaso- 
dilatation in patients with hypertension with captopril, ena- 
lapril, and cilazapril have been negative. The finding of the 
Trial in Reversing Endothelial Dysfunction (TREND) that 
the administration of quinapril to normotensive patients with 
coronary artery disease in part restores endothelial-mediated 
coronary vasodilation, as assessed by intracoronary adminis- 
tration of acetylcholine, has important implications for fu- 
ture therapy and raises several important questions. The dif- 
ferences in the TREND and previous studies of ACE 
inhibitors on endothelial dysfunction may be due to mecha- 
nistic differences in endothelial dysfunction in patients with 
coronary artery disease and hypertension. Although in gen- 
eral there has been a good correlation between endothelial 
dysfunction as assessed by forearm flow and coronary endo- 
thelial dysfunction as assessed by acetylcholine, these vascu- 
lar beds may be affected differently by therapeutic interven- 
tions, especially with an ACE inhibitor, which may affect 
shear stress and angiotensin II formation in different vascu- 
lar beds differently. Third, one needs to question whether the 
effect of quinapril on coronary endothelial dysfunction is a 
class effect or unique to quinapril. It will he necessary to 
test the effectiveness of other ACE inhibitors on coronary 
endothelial dysfunction in humans before concluding that 
the beneficial effects of quinapril are due to a class effect. 
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Experimental studies in a variety of animal species, 
disease models, and with a variety of angiotensin- 
converting enzyme (ACE) inhibitors have suggested 
that ACE inhibitors may have an important role in 
blocking the progression of and/or reversing endothe- 
lial dysfunction [1-6]. These studies have far reaching 
implications for the therapy of a number of important 
disease entities, including atherosclerosis and its con- 
sequences, hypertension, heart failure, and possibly 
diabetes mellitus. Endothelial dysfunction is thought 
to be an early common pathway for these and other 
diseases involving the vascular wall [7]. The produc- 
tion and release of nitric oxide (NO) by the normal 
endothelium is essential for the vasodilator effect of a 
number of physiologic and pharmacologic mediators, 
prevents the adherence and infiltration of monocytes 
onto and into the vascular wall, as well as preventing 
the adherence and activation of platelets with subse- 
quent thrombosis [7-10]. Thus, the finding in experi- 
mental studies that ACE inhibitors can prevent or 
reverse endothelial dysfunction has given hope to the 
prospect that these agents might have an effect on 
the natural history of several diseases that affect the 
vascular wall, beyond blood pressure reduction, pre- 
vention of left ventricular hypertrophy, and ventricu- 
lar remodeling. 
The mechanism by which ACE inhibitors prevent 
and/or reverse endothelial dysfunction is speculative. 
Angiotensin II has been shown to be an important 
oxidant [11,12]. At physiologic concentrations angio- 
tensin II has been shown to increase the production 
of superoxide ions and lipid peroxidase, as well as to 
increase macrophage-mediated oxidation of LDL cho- 
lesterol [11]. Free radical formation can interfere with 
the formation and/or release of nitric oxide from the 
endothelium [13]. Angiotensin II causes the oxidation 
of LDL cholesterol and facilitates the migration of 
LDL cholesterol into the vascular wall independent of 
its oxidation [11,14]. Angiotensin II has also been 
shown to stimulate various cytokines that attract 
monocytes and their infiltration into the vascular wall 
with subsequent foam cell formation [15]. Angiotensin 
II has also been shown to cause the release of endo- 
thelin [16], which in itself is an important mitogen and 
vasoconstrictor. Angiotensin II alone or in combina- 
tion with endothelin also causes vasoconstriction, an 
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increase in blood pressure, and shear stress, which 
could affect endothelial function [17]. ACE inhibitors, 
by blocking the formation of angiotensin II and/or by 
preventing bradykinin degradation, would tend to 
prevent these deleterious effects. Furthermore, ACE 
inhibitors have been shown to increase antioxidant de- 
fense mechanisms, such as superoxide dismutase [18], 
which would tend to prevent NO destruction. 
The extrapolation of these experimental studies 
and theoretic considerations to the clinical situa- 
tion has, however, been disappointing. For example, 
Creager and Roddy, in a study of patients with hyper- 
tension and endothelial dysfunction, could not demon- 
strate a beneficial effect of either captopril or enalapril 
administered for a 2 month period on endothelial- 
dependent forearm vasodilatation [19]. Similarly, Ki- 
owski et al, could not demonstrate a beneficial effect of 
the ACE inhibitor cilazapril on endothelial-dependent 
forearm vasodilatation in patients with hypertension 
treated for 20 weeks [20]. Although the acute adminis- 
tration of captopril has been reported to reverse endo- 
thelial dysfunction in hypertensive patients [21] this 
study was done during the administration of the drug, 
while the studies by Creager and Roddy [19] and Ki- 
owski et al. [20] were done after drug withdrawal to 
examine whether chronic drug administration had al- 
tered vascular structure and/or function. 
In view of these negative studies of chronic ACE 
inhibition in humans, it is of interest to find that the 
ACE inhibitor quinapril administered for 6 months to 
nonhypertensive patients with coronary artery dis- 
ease and endothelial dysfunction resulted in a signifi- 
cant reversal of coronary artery endothelial dysfunc- 
tion. The Trial in Reversing Endothelial Dysfunction 
(TREND) studied the effect of quinapril 40 mg daily 
or placebo in 105 patients with coronary artery dis- 
ease who at baseline coronary arteriography had de- 
monstrable endothelial dysfunction, as evidenced by 
a loss of vasodilatation to the intracoronary adminis- 
tration of acetylcholine [22]. The patients in this study 
all had single or double-vessel coronary artery disease 
(>50% diameter stenosis), requiring nonsurgical re- 
vascularization and one adjacent major coronary ar- 
tery with <40% diameter stenosis that had not been 
revascularized. Endothelial dysfunction had to be 
present in the adjacent coronary artery (a >-5% reduc- 
tion in mean lumen diameter or no response to acetyl- 
choline) to be included. Patients with a history of hy- 
pertension could be included if they were controlled 
with a systolic blood <160 mmHg and a diastolic pres- 
sure of <90 mmHg. At the end of the 6 month fol~ 
low-up period, the study drug was withdrawn for 3 
days and endothelial dysfunction was reevaluated by 
intracoronary acetylcholine. Patients randomized to 
quinapril were found to have had a significant im- 
provement in endothelial dysfunction of 12% com- 
pared with 0.8% at a dose of 10 -4 ml/1 of acetylcholine 
in those randomized to placebo (p = 0.002), without 
any significant effect of quinapril on systemic blood 
pressure. 
Virdis et al. [23] have also shown that captopril 
50 mg bid administered for 1 year to 16 patients 
with essential hypertension and angiographically 
normal coronary arteries, and then withdrawn for 2 
weeks, improved forearm blood flow in response to 
acetylcholine infusion in a subset of eight patients 
who had a positive dipyridamole echocardiographic 
stress test, suggestive of microvascular coronary 
artery disease. They also found a baseline abnor- 
mality in forearm blood flow to the endothelial- 
independent vasodilator nitroprusside, as well as an 
improvement in forearm flow in response to nitro- 
prusside after the year of therapy with captopril. 
This data suggests an improvement in vascular 
structure as a result of effective antihypertensive 
therapy rather than a change in endothelial function 
perse. A reversal of vascular structural abnormali- 
ties in patients with hypertension has been previ- 
ously seen in patients treated with an ACE inhibitor 
[24] as well as a calcium channel blocking agent [25]. 
Although there may have been a structural change 
in the coronary vessels of patients in the TREND 
[22] study, they had a vasodilator response to nitro- 
glycerin at baseline and did not show a change in 
their response to nitroglycerin after therapy with 
quinapril, suggesting that the primary effect of quin- 
april in this situation, in contrast to the study 
by Virdis et al. [23], was a change in endothelial 
function. 
The positive findings in the TREND study in re- 
gard to an improvement in endothelial function in pa- 
tients with coronary artery disease treated with quin- 
april compared with the negative findings in patients 
with hypertension treated with captopril, enalapril, 
and cilazapril [19,20,23], raise several important ques- 
tions that will need to be answered before the data 
from the TREND study [22] can be placed in proper 
prospective. 
First, the patients in the TREND study [22] all 
had angiographically proven coronary artery disease, 
whereas those in the studies by Creager et al. and 
Kiowski et al. [19,20] had hypertension without 
known coronary artery disease, and the patients stud- 
ied by Virdis et al. had angiographically normal coro- 
nary arteries. While endothelial dysfunction has been 
found in most patients with hypertension, it is not 
found in all patients [26], whereas the situation in pa- 
tients with angiographic evidence of atherosclerotic 
coronary artery disease appears to be more homoge- 
nous [27-29]. It is possible that endothelial dysfunc- 
tion in patients with hypertension is in some way 
mechanistically different from that in early athero- 
sclerosis. Shear stress may affect endothelial dysfunc- 
tion and vessel structure quantitatively or qualita- 
tively differently than lipid and/or other coronary risk 
factor-induced endothelial dysfunction. For example, 
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it could be postulated that oxidized LDL cholesterol 
and subsequent free radical formation might be more 
important in atherosclerosis-induced endothelial dys- 
function, while shear stress may be the critical factor 
in patients with hypertension without the accumula- 
tion of LDL cholesterol in the vascular wall and that 
a reduction in blood pressure, rather than a reduction 
in LDL cholesterol, might be more important in this 
situation. Hypertension and atherosclerosis could also 
have quantitative and or qualitatively different effects 
on the formation, release, or effect of NO on smooth 
muscle cells. 
Second, the studies by Creager and Roddy [19], 
Kiowski et al. [20], and Virdis et al. [23] focused on 
forearm-mediated endothelial dysfunction, while the 
TREND study [22] examined coronary endothelial 
dysfunction. In general, there has been a good corre- 
lation between endothelial dysfunction assessed by 
forearm flow and coronary endothelial dysfunction 
[27]. However, the endothelium in different vascular 
beds and in different sized arteries has been shown to 
differentially modulate the local conversion of anglo- 
tensin (AT) I to AT II [28]. Thus, it is possible that 
different vascular beds and segments within a vascu- 
lar bed respond differently to different therapeutic 
interventions depending upon local ACE concentra- 
tion and differential effects of the intervention on local 
shear stress. While it is convenient to study brachial 
artery endothelial dysfunction, one should be cautious 
in any extrapolation to other vascular beds without a 
careful prospective study of each intervention, espe- 
cially with an ACE inhibitor which may affect shear 
stress and AT II formation in different vascular beds 
differently. 
Third, one needs to question whether the effect 
demonstrated on the coronary endothelium by quin- 
april is a class effect of ACE inhibitors or is unique 
to quinapril or a particular group of ACE inhibitors. 
Quinapril is lipophilic and has been shown to be tightly 
bound to vascular ACE [32]. While on the basis of 
animal experiments one might predict that both lipo- 
philic ACE inhibitors such as ramapril [3] and rela- 
tively hydrophilic ACE inhibitors such as enalapril 
[4], as well as sulfhydro-containing [2] and non- 
sulfhydro-containing ACE inhibitors [3] would be ef- 
fective in humans, there may be important differences 
in the time and magnitude of their effectiveness. 
Thus, it will be necessary to test and demonstrate 
the effectiveness of other ACE inhibitors, such as the 
hydrophilic ACE inhibitors, on coronary endothelial 
dysfunction in humans before concluding that the ben- 
eficial effects of quinapril noted in the TREND study 
are a class effect. 
While these and other more fundamental questions 
will need to be answered by careful prospective clini- 
cal research over the next several years, it is reason- 
able to predict that the results of the TREND study 
[22], if confirmed, will have important implications, at 
least for patients with coronary artery disease. One 
would anticipate that quinapril and possibly other sire- 
ilar ACE inhibitors will prove effective in preventing 
the development of new atherosclerotic lesions, pro- 
gression of early atherosclerotic lesions, plaque rup- 
ture, and possibly thrombosis after plaque rupture, 
with a resultant decrease in ischemic events. A rever- 
sal of coronary endothelial dysfunction should also 
have an important effect on coronary vasomotor tone, 
with a consequent improvement in exercise and/or "si- 
lent" myocardial ischemia. Previous studies of ACE 
inhibitors have not, however, shown a uniform bene- 
ficial effect on angina pectoris. Cleland et al. [33], for 
example, found in fact that captopril increased the 
frequency of anginal episodes and use of nitroglycerin, 
possibly by inducing a coronary "steal." This and 
other studies testing the antiischemic effect of ACE 
inhibitors were, however, for the most part of rela- 
tively short duration, around 3 months. It may re- 
quire longer term administration, possibly 6 months, 
before endothelial dysfunction is reversed as seen in 
the TREND study [22]. Conversely, as mentioned 
earlier, the ACE binding characteristics of quinapril 
[32] and possibly other lipophilic ACE inhibitors may 
make them unique. One might also postulate that the 
beneficial effects of quinapril on coronary endothelial 
dysfunction seen in TREND [22] would complement 
strategies such as LDL-cholesterol lowering. LDL- 
cholesterol lowering by decreasing the potential for 
oxidation of LDL cholesterol has been shown to pre- 
vent and/or reverse endothelial dysfunction both in 
animals and humans [34-36]. The reversal of endothe- 
lial dysfunction by LDL-cholesterol reduction is asso- 
ciated with a significant decrease in new coronary 
artery lesion formation, progression of minimal coro- 
nary artery disease, and ischemic events [37-39]. 
These mechanisms, as mentioned earlier, are common 
to ACE inhibitors, and hence ACE inhibitors could be 
postulated to have a synergistic or additive effect to 
LDL-cholesterol lowering strategies as well as an in- 
dependent effect in patients in whom LDL cholesterol 
is not elevated or pathophysiologically of importance. 
Whether or not these predictions will prove accu- 
rate will in part be answered in the near future by 
ongoing large-scale prospective studies, such as 
QUIET [40], HOPE [41], and PEACE [42], in which 
the effect of ACE inhibitors on ischemic events and 
mortality are being investigated. Regardless of the 
outcome of these studies, it is likely that the provoca- 
tive findings in the TREND study [22], in conjunction 
with previous experimental studies, will stimulate 
further basic and clinical investigation, and the likeli- 
hood that we will have a better understanding and 
possibly new opportunities for the secondary and pos- 
sibly primary prevention of ischemic heart disease and 
other diseases affecting the vascular wall in which en- 
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